International harmonization of trial parameters in malignant lymphoma.

International harmonization of trial parameters in malignant lymphoma. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

International harmonization of trial parameters in malignant lymphoma. Abstract Text:

Despite the publication of standardized response criteria for non-Hodgkin's lymphomas by Cheson et al., an examination of current trial parameters in nine international lymphoma study groups by the working group for quality management (WG-QM) of the Competence Network Malignant Lymphoma found differences or even missing definitions. This finding led V. Diehl, B. Cheson, and B. Pfistner to found an international project to harmonize trial parameters for malignant lymphoma. Committees of international experts on various aspects of clinical trials design and execution were formed with the charge of summarizing the current status of each aspect of trial conduct, developing a consensus as to the most current definitions, and publishing the report of those deliberations.

International harmonization of trial parameters in malignant lymphoma. Publishing Authors By Initials

For similar neoplasms: neoplasms by histologic type: lymphoma research abstracts see: neoplasms: neoplasms by histologic type: lymphoma research

PUBMED ID PMID:

MEDLINE DATE:

International harmonization of trial parameters in malignant lymphoma. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: European journal of haematology. Supplementum

VOLUME:

Page Numbers: 53-4

Journal Abbreviation:

ISSN: 0902-4506

DAY: 26

MONTH: Jul

YEAR: 2005

International harmonization of trial parameters in malignant lymphoma. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8703474

International harmonization of trial parameters in malignant lymphoma. Keywords Mesh Terms:

KEYWORDS: Lymphoma

MESH TERMS: therapy

Chemical & Substance for Abstract: International harmonization of trial parameters in malignant lymphoma. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for International harmonization of trial parameters in malignant lymphoma.

AFFILIATION: Competence Network Malignant Lymphoma (KML) and German Hodgkin Study Group (GHSG), University Clinics Cologne, Köln, Germany. harmonisation@biometrie.uni-koeln.de

Country: Denmark

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Eur J Haematol Suppl

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

International harmonization of trial parameters in malignant lymphoma Related Publications

• Anti-CD20 Monoclonal Antibodies in the Treatment of Indolent Lymphoma and CLL.
• Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study.
• Ghostwriting.
• Highlights of the 2008 international conference on malignant lymphoma.
• International harmonization of trial parameters in malignant lymphoma.
• Lenalidomide for the treatment of B-cell malignancies.
• Letter from the editor.
• Meeting Highlights from: The 10th International Conference on Malignance Lymphoma; Lugano, Switzerland; June 4-7, 2008.
• Most important accomplishments.
• Needle tract seeding after bone marrow biopsy in non-Hodgkin lymphoma.
• New staging and response criteria for non-hodgkin lymphoma and hodgkin lymphoma.
• Phase II Multicenter Study of Bendamustine Plus Rituximab in Patients With Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin's Lymphoma.
• Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma.
• Pineal region tumors: computed tomographic-pathologic spectrum.
• Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153.
• Rational approaches to design of therapeutics targeting molecular markers.
• Recent Advances in the Treatment of CLL and NHL.
• Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901.
• The International Harmonization Project for response criteria in lymphoma clinical trials.
• The role of FDG-PET scans in patients with lymphoma.